Esmolol

Esmolol is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol exerts its antiarrhythmic effect by activating Neurokinin 1 Receptor. Esmolol attenuates post resuscitation myocardial dysfunction. Esmolol improves diabetic wound healing by inhibiting aldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers[1][2][3].

Product Specifications

CAS Number

[81147-92-4]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Adrenergic Receptor; Aldose Reductase; Apoptosis; Caspase; Neurokinin Receptor

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Cancer; Endocrinology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/esmolol.html

Smiles

O=C(OC)CCC1=CC=C(OCC(O)CNC(C)C)C=C1

Molecular Formula

C16H25NO4

Molecular Weight

295.37

Precautions

P261-P280-P302+P352

References & Citations

[1]Kulkarni SA, et al. Novel topical esmolol hydrochloride improves wound healing in diabetes by inhibiting aldose reductase, generation of advanced glycation end products, and facilitating the migration of fibroblasts. Front Endocrinol (Lausanne) . 2022 Aug 23;13:926129. |[2]Wang LL, et al. Esmolol activates endogenous neurokinin activity inhibiting infarction-induced arrhythmias in rats: novel mechanisms of anti-arrhythmia. Regul Pept. 2013 Sep 10;186:116-22. |[3]Zhang Q, et al. Combination of epinephrine with esmolol attenuates post-resuscitation myocardial dysfunction in a porcine model of cardiac arrest. PLoS One. 2013 Dec 18;8 (12) :e82677.